We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-4.33%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.5B
AUM Growth
-$794M
Cap. Flow
+$217M
Cap. Flow %
1.89%
Top 10 Hldgs %
81.68%
Holding
128
New
8
Increased
22
Reduced
12
Closed
5

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$146M
2
ABLX
Ablynx NV
ABLX
+$94M
3
PHXM
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
+$73M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$54.2M
5
ACAD icon
Acadia Pharmaceuticals
ACAD
+$45M

Top Sells

Rank Stock Value
1
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$170M
2
AKAO
Achaogen Inc
AKAO
+$47.2M
3
NDRM
NeuroDerm Ltd. Ordinary Shares
NDRM
+$22.2M
4
EXEL icon
Exelixis
EXEL
+$15.3M
5
LOXO
Loxo Oncology, Inc
LOXO
+$8.85M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRBP icon
76
Corbus Pharmaceuticals
CRBP
$201M
$4.69M 0.04%
+22,024
New +$4.71M
ECYT
77
DELISTED
Endocyte, Inc. Common Stock
ECYT
$4.65M 0.04%
+1,087,323
New +$5.18M
AAAP
78
DELISTED
Advanced Accelerator Applications S.A.
AAAP
$4.5M 0.04%
55,125
-2,188,137
-98% -$170M
ACOR
79
DELISTED
Acorda Therapeutics
ACOR
$4.42M 0.04%
1,716
-2,613
-60% -$7.43M
IFRX icon
80
InflaRx
IFRX
$309M
$4.19M 0.04%
+200,000
New +$3.61M
OVID icon
81
Ovid Therapeutics
OVID
$547M
$3.29M 0.03%
333,333
– –
ARAV
82
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.14M 0.03%
237,718
-1,818
-0.8% -$23.4K
AKTX
83
Akari Therapeutics
AKTX
$15.3M
$3.02M 0.03%
871
+250
+40% +$964K
TRIL
84
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.97M 0.03%
409,323
-4,374
-1% -$36.2K
EPZM
85
DELISTED
Epizyme, Inc
EPZM
$2.92M 0.03%
232,481
– –
RNAC icon
86
Cartesian Therapeutics
RNAC
$304M
$2.78M 0.02%
9,457
-203
-2% -$88.7K
VIRX
87
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.74M 0.02%
21,190
– –
NVAX icon
88
Novavax
NVAX
$1.47B
$2.48M 0.02%
100,000
– –
TNXP icon
89
Tonix Pharmaceuticals
TNXP
$215M
– –
0
– –
KRYS icon
90
Krystal Biotech
KRYS
$10.3B
$2.1M 0.02%
200,000
– –
KPTI icon
91
Karyopharm Therapeutics
KPTI
$44.5M
$2.08M 0.02%
14,466
– –
NTRA icon
92
Natera
NTRA
$47.9B
$2.06M 0.02%
228,676
– –
TRVN
93
DELISTED
Trevena, Inc.
TRVN
$1.52M 0.01%
1,520
– –
RARX
94
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$1.51M 0.01%
177,952
– –
CLLS
95
Cellectis
CLLS
$342M
$1.46M 0.01%
50,000
– –
DVAX
96
DELISTED
Dynavax Technologies
DVAX
$1.4M 0.01%
75,000
– –
AKAO
97
DELISTED
Achaogen Inc
AKAO
$1.31M 0.01%
122,482
-3,764,396
-97% -$47.2M
JNCE
98
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
$1.27M 0.01%
100,000
– –
INFI
99
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$1.18M 0.01%
580,400
– –
MDWD icon
100
MediWound
MDWD
$171M
$1.01M 0.01%
32,286
– –
1 2 3
4
5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2017 Portfolio in Review

As of Q4 2017, Julian Baker held 128 positions worth $11.5B, down 6.4% from $12.3B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Julian Baker's Q4 2017 filing shows 8 new, 22 increased, 12 reduced and 5 closed positions. Its largest new stake was Ablynx NV: 4,161,118 shares worth $104M. The largest sale was Advanced Accelerator Applications S.A., an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q4 2017 buy was Ablynx NV: 4,161,118 shares worth $104M.
  • Julian Baker added most to BioMarin Pharmaceuticals in Q4 2017, an estimated $146M increase.
  • Julian Baker's biggest Q4 2017 reduction was Advanced Accelerator Applications S.A., cutting an estimated $170M.
  • Julian Baker fully exited NeuroDerm Ltd. Ordinary Shares in Q4 2017, selling an estimated $22.2M.
  • Julian Baker's ten largest holdings make up 82% of its $11.5B portfolio in Q4 2017.
  • Julian Baker opened 8 new positions and closed 5 in Q4 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.5B.

Based on Baker Bros. Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.